Rapid clearance of antigen complexes using novel antibodies
US-9738722-B2 · Aug 22, 2017 · US
Methods and compositions for inhibiting CD32B expressing cells
US11447552B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11447552-B2 |
| Application number | US-201113301464-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2011 |
| Priority date | May 30, 2007 |
| Publication date | Sep 20, 2022 |
| Grant date | Sep 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
First claim
Opening claim text (preview).
We claim: 1. An antibody comprising: at least one amino acid substitution in the Fc region comprising S267E, wherein the numbering is according to the EU index, as in Kabat; and a light chain variable region comprising SEQ ID NO: 1; and a heavy chain variable region comprising SEQ ID NO: 2. 2. The antibody according to claim 1 , further comprising an amino acid substitution L328F in the Fc region. 3. The antibody according to claim 1 , consisting of amino acid substitutions S267E and L328F in the Fc region. 4. An anti-CD19 antibody comprising: a) a light chain variable region comprising SEQ ID NO:1; b) a heavy chain variable region comprising SEQ ID NO:2; and c) a variant Fc human IgG domain comprising the amino acid substitution S267E, wherein the numbering is according to the EU index as in Kabat. 5. The antibody according to claim 4 , wherein the variant Fc human IgG domain further comprises an amino acid substitution L328F. 6. The antibody according to claim 4 , wherein the variant Fc human IgG domain consists of amino acid substitutions S267E and L328F in the Fc region.
Assignees
Inventors
Classifications
Constant or Fc region; Isotype · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Hinge · CPC title
- C07K16/00Primary
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11447552B2 cover?
- The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
- Who is the assignee on this patent?
- Chu Seung Yup, Desjarlais John R, Karki Sher Bahadur, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).